Hepatocellular carcinoma (HCC) with a focus on diagnosis and screening
This study aimed to analyze clinical and laboratory parameters and their association with long-term outcomes in patients who underwent liver transplantation for hepatocellular carcinoma treatment, according to the etiology of the underlying chronic liver disease, in order to identify predictors of response to this therapeutic modality. METHODS: Demographic, clinical, and laboratory data from a cohort of 134 patients who underwent orthotopic liver transplantation for hepatocellular carcinoma treatment at a referral center in Brazil were retrospectively selected and compared according to the etiologic group of the underlying...
Recent studies have reported albumin-bilirubin (ALBI) grade affected the prognosis of patients with hepatocellular carcinoma (HCC). To more precisely evaluate the relationship among the ALBI grade and the prognosis of patients with HCC after liver resection. We systematically retrieved articles from PubMed, Web of Science, Cochrane Library, and CNKI. The prognostic value of ALBI grade on overall survival (OS) and recurrence-free survival (RFS) of patients with HCC after liver resection was evaluated by pooled hazard ratio (HR) with 95% confidence interval (CI).Through multiple databases search, we enrolled 20 high-quality ...
Conclusion The results show that vitamin D status and VDBP levels are associated with liver cirrhosis severity and patients’ mortality, possibly through a proinflammatory immune response.
Conclusion FIB4A is a potential marker for early detection of NBNC-HCC in patients with diabetes mellitus. However, further studies are needed to confirm these findings.
Objectives: Toronto hepatocellular carcinoma risk index is developed to stratify cirrhotic patients according to 10-year hepatocellular carcinoma risk. We aimed to validate the performance of Toronto hepatocellular carcinoma risk index in a large Turkish cohort. Materials and methods: We retrospectively reviewed the database of 1287 cirrhotic patients followed-up in a 10-year period (February 2008 to January 2018). All patients were stratified into three groups based on the Toronto hepatocellular carcinoma risk index score as follows: low-risk, 240. Area under the curve and optimal cutoff value of Toronto hepatocellul...
Publication date: Available online 2 June 2020Source: Pharmacological ResearchAuthor(s): Kuan-Fu Liao, Yu-Hung Kuo, Shih-Wei Lai
Conclusions: Image fusion using pre-procedural MRI allows for ablation of CT-'invisible' liver tumors that are otherwise untreatable. Moreover, local oncological control was higher in metastatic liver tumors versus matched controls which suggests it could be useful tool for all stereotactic radiofrequency ablation procedures. PMID: 32484004 [PubMed - in process]
Publication date: Available online 1 June 2020Source: Pathology - Research and PracticeAuthor(s): Zhi-Yun Zhang, Meng Lu, Ze-Kun Liu, Hao Li, Yu-Le Yong, Ren-Yu Zhang, Zhi-Nan Chen, Huijie Bian
Authors: Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, Wei Y, Zhai R, Lei B, Yu H, Jiao X, He S Abstract [This corrects the article DOI: 10.18632/oncotarget.3713.]. PMID: 32477467 [PubMed - in process]
Conclusion: TOP2A, NDC80, CDK1, CCNB1, KIF11, BUB1, CCNB2, CCNA2 and TTK were hub genes in HCC, which may be potential biomarkers of HCC and targets of HCC therapy. PMID: 32476992 [PubMed]